替罗非班在急性ST段抬高型心肌梗死中的合理应用  

Application of Tirofiban in Acute ST-Segment Elevation Myocardial Infarction

作　　者：姜玉蓉[1] 冯彩琴[1] 卢振华[1] 

机构地区：[1]三峡大学第一临床医学院宜昌市中心人民医院心内科,湖北宜昌443003

出　　处：《心血管病学进展》2010年第6期911-913,共3页Advances in Cardiovascular Diseases

摘　　要：直接经皮冠状动脉介入治疗中尽早、有效、合理的抗血小板治疗无论是对于开通梗死相关冠状动脉还是防止再梗死等临床事件均具有十分重要的意义。替罗非班是一种高选择性非肽类、短效血小板膜糖蛋白Ⅱb/Ⅲa受体拮抗剂,具有很强抗血小板聚集作用,可与阿司匹林和氯吡格雷联合应用于急性ST段抬高型心肌梗死患者。It is important to use antiplatelet therapy in the early stages of primary percutaneous coronary intervention for opening the infarct-related coronary artery and/or preventing re-infarction.Tirofiban,a highly selective non-peptide and short-acting platelet glycoprotein Ⅱb/Ⅲa receptor antagonist,can be combined with aspirin and clopidogrel for use in acute ST-segment elevation myocardial infarction as it has a strong antiplatelet aggregation effect.

关 键 词：血小板膜糖蛋白Ⅱb/Ⅲa受体拮抗剂 替罗非班 心肌梗死 

分 类 号：R542.22[医药卫生—心血管疾病] R973.2[医药卫生—内科学]